BACKGROUND: While much has been published on utilization of anti depressants and associated resource use, surprisingly little information is available on the relationship between a change in antidepressant agent and health care utilization. Given that many patients will not respond to initial therapy (and therefore would be candidates for switching treatment) and the array of antidepressant medications on the market, information on the impact of switching would be beneficial to both providers and policymakers.
METHODS: Using an administrative claims database of 36 million members from 61 health plans, this retrospective cohort analysis examined patients who had (1) a diagnosis of major depressive disorder (MDD, International Classification of Diseases, Ninth Revision, Clinical Modification [ICD9CM] code 296.2x for MDD single episode, 296.3x for MDD recurrent episode, 300.4 for dysthymic disorder, and 311 for depressive disorder not else where classified) and (2) a newly prescribed antidepressant during the year 2002. Costs were defined as amounts paid by health plans for all inpatient, outpatient, physician and pharmacy services (i.e., allowed charges after subtraction of member costshare). Depressionrelated costs were defined using (1) medical claims with primary diagnosis of depression and (2) pharmacy claims for antidepressants. Using an index date of the first antidepressant claim, 12 months of preindex and post index data were available for all eligible patients. Switching was defined as occurring between the SSRIs and venlafaxine (i.e., patients who switched within the SSRI drug class across different SSRIs were treated as non switchers until they switched to venlafaxine), and there was no minimum or maximum gap in therapy. The SSRIs included fluoxetine, citalopram, sertraline, and paroxetine; the only SNRI on the market at the time was venlafaxine. Multivariate regression analyses determined predictors of switching and factors influencing overall and depressionrelated costs, while controlling for confounding factors. For the 12month period following the index date (fixed length of followup), the study compared perpatient peryear (PPPY) costs for (1) patients who switched versus those who did not switch and (2) patients with single versus multiple trials of SSRI for the subgroup of patients who switched from an SSRI to venlafaxine. For the time periods before versus after the switch (variable lengths of followup), perpatient means and medians of monthly cost averages (with followup periods < 1 month set to 1 month for 16 Monthly mean depressionrelated pharmacy costs increased by 62.2% following a switch from an SSRI to venlafaxine (from $45 [$38 ] to $73 [$62], P < 0.001) and declined by 17.3% following a switch from venlafaxine to an SSRI (from $52 [$45 ] to $43 [$38], P < 0.001). After adjustment for multiple covariates including demographic characteristics, 10 selected comorbidities, and physician specialty, general linear models with log transformed costs as the dependent variables demonstrated significant associations between switching and total costs (both allcause and depressionrelated) in both the SSRI and the venlafaxine cohorts.
D
epression is a common psychiatric disorder with significant clinical, economic, and quality-of-life consequences. Despite the availability of a wide array of antidepressants to treat depression, between 30% and 50% of patients with major depression fail to respond to an initial course of antidepressant therapy. [1] [2] [3] A clinician survey published in 2000 showed that 44% of 392 physicians treating patients with depression reported that they opt to switch selective serotonin reuptake inhibitor (SSRI) non-responders to a non-SSRI therapy. 4 Furthermore, a retrospective claims study of patients diagnosed with depression found that treatment-resistant patients are more than twice as likely to be hospitalized and incur more than twice the medical cost of non-resistant patients. 5 Although some patients fail to respond because of inadequate antidepressant dose or duration of therapy, a sizable proportion of patients exhibit resistance to 1 or more adequate antidepressant treatments. 6 The treatment of refractory depression poses a particular challenge. Clinicians essentially have 3 choices-to switch to another antidepressant, to add a second medication, or to augment the current medication with additional/alternative drug therapies and/or cognitive therapies. 7, 8 Clinical treatment guidelines also suggest pathways for treating patients, and in the event of non-response, suggest the option of switching patients to an alternative antidepressant. 1, 9 Switching of antidepressants can happen either within the same class of drugs or to a different class. Several classes of drugs are prescribed in the treatment of depression, including trazodone; SSRIs, such as fluoxetine, paroxetine, and sertraline; selective norepinephrine reuptake inhibitors (SNRIs), such as venlafaxine; and tricyclic antidepressants (TCAs), such as amitriptyline and nortriptyline. 1, 9 The guidelines also recommend that, if a patient fails to respond to a drug in 1 antidepressant class, switching to a medication in another class may prove effective.
10
Although most antidepressants are believed to be equally efficacious for the treatment of depression, based on clinical trials, they are not necessarily equally effective, based on experience in naturalistic settings. That is, the choice of medication may lead to varying outcomes because of individual tolerability, response, and adherence.
10 A Cochrane Systematic Review in 2005 of fluoxetine, the oldest SSRI, versus TCAs, other SSRIs, and the newer agents, concluded that, while clinical studies have shown statistically significant differences in efficacy and tolerability, the clinical importance of these differences is not known.
11
Similarly, the choice of a specific second agent largely depends on the individual clinician's judgment regarding side effects, safety, patient preference, cost, drug interaction potential, and positive or negative effects of the agent on concomitant medical or psychiatric disorders.
7
The benefits and consequences of switching antidepressants have gained renewed attention with the publication of the STAR*D (Sequenced Treatment Alternatives to Relieve Depression) trial results. 12, 13 The study compared various treatment options for those who did not attain symptomatic remission with citalopram, an SSRI. Treatment options included switching patients to cognitive therapy, sertraline (an SSRI), venlafaxine (an SNRI), or bupropion (a third category of antidepressant).
12 Based on the 17-item Hamilton Rating Scale for Depression (HRSD-17), there were no significant differences in remission rates between the 3 medication switch options (24.8% for venlafaxine, 21.3% for bupropion, and 17.6% for sertraline). Tolerability and incidence of adverse events also did not differ among the 3 medications, suggesting that any of the 3 is a reasonable choice for patients with citalopram-resistant depression. Of note, patients who switched to cognitive therapy had similar response and remission rates to those assigned to medication strategies and had fewer side effects.
Other studies have found no clear evidence to support one medication strategy over another. Using 3 randomized clinical trials (RCTs), including STAR*D, 12, 14, 15 Ruhe et al. performed a systematic review. 16 Pooled results from 8 RCTs and 23 open-label studies showed a modest and "clinically equivocally advantageous" increased remission rate for venlafaxine over SSRIs (number needed to treat = 13 [95% confidence interval (CI) = 9.1-25.0]). Given the lack of evidence to support a preferred option, the authors noted, "After a first SSRI, any switch within or between classes of anti depressants appears legitimate." 16 Another recent review of 14 clinical studies on venlafaxine (5 randomized and
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• Factors predicting an increased likelihood of making an antidepressant class switch include: patient age < 40 years, Medicaid enrollment, use of anxiolytic medication in the 12 months prior to initiation of antidepressant therapy, receipt of care from a psychiatrist, and higher all-cause medical costs prior to initiating antidepressant medication.
• Mean (median) days of antidepressant drug supply in the 12 months following initiation of SSRI drug therapy were 240.6 (248) for switchers and 190.7 (180) for non-switchers; for patients with index drug therapy with venlafaxine, the total days of drug therapy in the 12 months of follow-up were 213.6 (210) for switchers and 204.9 (210) for non-switchers. • In the 12 months following initiation of antidepressant therapy, patients switching antidepressant drug classes incurred higher all-cause costs and higher depression-related costs than did patients who made no switch of antidepressant class.
• Among patients switching from either an SSRI or venlafaxine, mean monthly depression-related medical costs (excluding antidepressant drug costs) decreased by more than 60% after switching. Additionally, for patients who switched from venlafaxine to an SSRI, antidepressant drug cost declined after the switch.
9 non-randomized) concluded that switching to an antidepressant of a different mechanism of action may reduce the likelihood of relapse or recurrence in patients with treatment-resistant depression. 17 However, the author noted that comparative studies do not uniformly find either SSRIs or venlafaxine to be superior. As a result, both within-class and out-of-class medication switches are reasonable second-step options for the treatment of depression.
Given the large number of drug therapy options and the interest in achieving clinical outcomes at lower cost, there may be an increasing tendency for clinicians to switch drug therapies. However, for managed care payers, determining the impact of drug switching is muddled, since the question of which medication switch option provides the greatest clinical benefit is unsettled. When patients are switched to alternative antidepressants, it is not clear what to expect in terms of cost and outcomes. 18, 19 The current study was designed to determine the pharmacy and total direct medical costs associated with antidepressantclass switching. Although evidence is unclear both for switches within class and outside, we focused on drug switching between 2 commonly used antidepressant classes, namely SSRIs and venlafaxine, because potential exists for varying outcomes. At the time of the study, venlafaxine was the only SNRI widely available. Since the literature on relative clinical efficacy of these 2 drug classes was fairly rich, albeit inconclusive, our goal was to examine to what extent drug-class switching occurs in clinical practice and what are the cost consequences of switching antidepressants between these 2 drug classes.
Although comparisons were made between switchers and non-switchers, the present study did not explore reasons for drug-class switching, the clinical drivers behind the economic impact of switching therapies, or the symptomatic remission rates resulting from switching. This study solely evaluated the resource utilization and cost associated with switching between SSRIs and venlafaxine. records include National Drug Code (NDC) numbers and days supply and quantity dispensed. All medical and pharmacy claims include dates of service. Costs were defined as amounts paid by health plans for all inpatient, outpatient, physician, and pharmacy services (i.e., allowed charges after subtraction of member cost-share). Hospital service settings were identified based on provider type and location fields present for each observation. Emergency room (ER) visits were further identified based on the presence of CPT-4 codes indicating care provided in an ER setting. Additional data elements included demographic variables (age, gender, geographic region), health plan type (e.g., HMO, PPO), payer type (e.g., commercial, self-pay), provider specialty, and start and stop dates for plan enrollment.
■■
Because all pertinent patient information in the database is encrypted and de-identified, and no patient contact was involved, no informed consent or approval by an institutional review board was sought (i.e., the data source was fully Health Insurance Portability and Accountability [HIPAA] compliant).
Sample Selection
Patients aged ≥ 18 years were included in the analysis if they had a pharmacy claim for either an SNRI (venlafaxine) or SSRI (citalopram, fluoxetine, paroxetine, or sertraline) from January 1, 2002, through December 31, 2002. The date of first antidepressant claim during that period was assigned as an index date. From that date, 12 months of pre-index and post-index data were collected for all health plan-eligible patients. Patients were excluded from the analysis if they had any claims for an antidepressant (venlafaxine, SSRI, or other antidepressant drugs) for a 1-year period prior to the index date. Study patients were also required to have a diagnosis of major depressive disorder (MDD, ICD-9-CM codes: 296.2x for MDD single episode, 296.3x for MDD recurrent episode, 300.4 for dysthymic disorder, and 311 for depressive disorder not elsewhere classified) in the 12 months prior to the index date. Finally, patients had to have continuous eligibility for the 24-month period centered on the index date. This was done to ensure complete baseline and follow-up information on all patients in the study.
Study Groups and Definition of Switching
Switching was defined as occurring between the SSRIs and venlafaxine (i.e., patients who switched within the SSRI drug class across different SSRIs were treated as non-switchers until they switched to venlafaxine). In identifying drug switches, there was no minimum or maximum gap in therapy (i.e., there could have been several months gap in therapy between the index drug and the new drug).
Two mutually exclusive study groups were identified based on the index pharmacy claim, either venlafaxine or an SSRI. Within each cohort, we identified switchers and non-switchers to the other drug class based on their first switching of drug class (switching back to the same drug class was rare). Among the SSRI switchers (those who switched from an SSRI to venlafaxine), we also compared single versus multiple SSRI users prior to drugclass switching.
Measures
The analyses were performed at 3 levels. First, we compared switchers and non-switchers within the 2 drug classes in terms of their characteristics and cost and utilization patterns. Second, we compared the pre-switch with the post-switch cost and utilization for drug-class switchers. These measures were based on cost and utilization for the time periods that patients spent prior to switching drug class (pre-switch) and after switching drug class (post-switch). Third, we compared SSRI switchers who switched from a single SSRI to venlafaxine with those who cycled through 2 or more SSRIs before switching drug class. Costs were aggregated for patients for all-cause and depression-related causes into medical (including hospital), pharmacy, and overall categories using a cost assignment algorithm based on primary diagnosis and pharmacy claims. Depression-related costs were defined using (1) medical claims with primary diagnosis of depression and (2) pharmacy claims for antidepressants. Antidepressants were identified using the Universal System of Classification (USC) codes (see Appendix).
Statistical Analysis
For the analyses of factors associated with antidepressant switching, descriptive analyses compared switchers versus non-switchers for each class (SSRI and venlafaxine). A logistic regression model with switching as a binary dependent variable (yes or no, coded as 1 or 0) was used to determine the likelihood of switching, controlling for index medication (citalopram, sertraline, paroxetine, and fluoxetine, with venlafaxine as the omitted [reference] group), patient demographics (categories: aged 40-59 years, aged 60-69 years, aged 70+ years, with aged 18-39 years as the omitted group); gender (female, with male as the omitted group), payer (Medicare, Medicaid, self-insured, other/ unknown, and commercially insured as the omitted group), provider specialty (internal medicine, psychiatry, psychology, other, and general practitioner/family practitioner [GP/FP] as the omitted group), and costs for the 12-month period prior to the index date, log-transformed to address skewness typical of cost data. In addition, dummy variables for the 10 , and the type of depression (MDD single episode, MDD recurrent, dysthymic disorder, and depressive disorder not elsewhere classified) encountered by these patients in the 12 months prior to antidepressant initiation were also included in the model. The list of predictors also included anxiety (300.0x), post-traumatic stress disorder (PTSD or "acute reaction to stress," 308.xx), substance abuse (303.xx, 304.xx, 305.xx), and anxiolytic use. Descriptive analyses also examined total days supply across both drug classes as well as mean length of therapy for the index medication, defined as (a) the last prescription date of index medication plus days supply as of the last prescription date minus (b) the index date.
Multivariate regression technique (general linear model, GLM) was used to compare switchers' and non-switchers' post-index costs, controlling for the same set of covariates as in the logistic regression analysis, with the exception that pre-index cost was included in the logistic regression analysis but not in the GLMs. Post-index treatment costs were log-transformed to account for heteroskedasticity. We did not attempt to retransform the data to produce adjusted cost estimates because the sole purpose of our multivariate analysis was to validate the descriptive analytic results. Because the dependent variable was log-transformed, the coefficient estimates are semi-elasticities, for which the interpretation of the coefficient estimates requires some care. For a continuous explanatory variable, the coefficient estimate beta represents the proportional change in the level of cost for a unit change in the explanatory variable, holding all other variables constant. In other words, for a unit increase in the explanatory variable, cost increases by 100 beta percent. For a dichotomous explanatory variable (i.e., with a value of 0 or 1, such as the switching status), the coefficient estimate represents the factor by which cost would be higher or lower for the switchers relative to non-switchers. By exponentiating the estimated coefficient and subtracting 1, it is possible to interpret the result as a percentage change from the reference group. Using the delta method, 20 we estimated and reported the standard error associated with the estimated coefficient for the switching status variable.
Four separate GLMs were run. First, 2 separate models with dependent variables equal to all-cause costs were run: 1 for patients whose index medication was an SSRI (n = 43,653) and a second model for patients whose index medication was venlafaxine (n = 5,297). These models were then repeated with the dependent variable changed to depression-related costs. For all 4 models, the primary variable of interest was the impact of switching medications. For the models estimated for the SSRI cohort, fluoxetine, citalopram, and sertraline were also included as binary variables with paroxetine as the omitted (reference) category. For the models estimated for the venlafaxine cohort, no additional variables were included, because venlafaxine was the single drug in the category.
Among patients switching from their index medication class, descriptive analyses compared differences in costs between the pre-switch and post-switch periods. Pre-switch and post-switch periods were based on the date of switch (the switch date was included in the post-period). Monthly averages were calculated for pre-switch and post-switch periods to normalize the comparison, because the number of days before and after switching varied by patient. The denominator for the calculation was the
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number of months rounded to the nearest whole month (e.g., 35 days was rounded to 1 month). For patients with less than 1 month of observation in either the pre-switch or post-switch time periods, 1 month was used as the denominator in the calculation. In calculating the per-patient mean and median values, no weighting for length of observation was made (i.e., each patient's outcomes were given the same weight irrespective of the number of months of pre-switch and post-switch observation.) Comparisons of pre-switch and post-switch costs were tested for significance using the repeated measures (paired) t test. Multivariate regression analyses were not conducted when comparing pre-switch and post-switch results, because the independent factors available in the data were based on patient-level characteristics that remained consistent between the pre-switch and post-switch periods, and, therefore, controls were not available to further account for cost differences between the 2 periods.
Finally, comparison of single SSRI users versus multiple SSRI users, who eventually switched to venlafaxine, was done using descriptive and multivariate analyses. Descriptive tables compared pre-switch and post-switch costs for the single versus multiple SSRI users, while GLMs assessed the relationship between costs (dependent variables) and a dichotomous indicator of whether the patient had 1 SSRI or more than 1 SSRI before switching to venlafaxine, controlling for the same covariates as in the logistic regression analysis including the pre-index cost. Descriptive comparisons were made using t tests or chi-square tests, depending on whether the variable was continuous or discrete, respectively. The analyses were performed using SAS software package 8.2 (SAS Institute, Inc., Cary, NC). The significance level was set at 0.05.
■■ Results
The patient selection criteria described earlier led to a sample of 48,950 patients in the index medication cohorts. Of these, 5,297 patients (10.8%) initiated therapy on venlafaxine, while the remaining 43,653 (89.2%) were initiated on an SSRI (Figure) . Of the initial SSRI users, 1,645 (3.8%) switched to venlafaxine after a mean of 3.25 pharmacy claims, with a mean length of therapy of 114.3 days of SSRI therapy compared with a mean of 5.45 claims (216.8 days) for SSRI users who did not switch therapy (P < 0.001, Table 1 ). Of the initial venlafaxine users, 733 (13.8%) switched therapy to an SSRI after a mean of 2.91 claims (100.2 days) compared with a mean of 6.29 (233.0 days) for venlafaxine users who did not switch therapy (P < 0.001). Mean total days supply of antidepressants (SSRI and venlafaxine) were, respectively, 240.6 and 190.7 for switchers and non-switchers in the SSRI cohort (P < 0.001) and 213.6 and 204.9 for switchers and non-switchers in the venlafaxine cohort (P = 0.043). For switchers, these days supply totals include both the pre-switch and post-switch periods (i.e., all drug classes used during the 12-month study period).
With respect to payer type, 78% and 72% of venlafaxine and SSRI patients, respectively, were enrolled in commercial plans, and 4% of venlafaxine and 7% of SSRI patients were enrolled in Medicare or Medicaid. Additional descriptive characteristics of the study sample were noted (not shown in tables):
• Nearly three quarters of patients (72%) initiated therapy within 3 months of their depression diagnosis, 83% within 6 months, and more than 90% within 9 months. • Patients were primarily enrolled in managed care plans, with 44% in HMOs, 32% in PPOs, 15% in POS plans, and the remaining patients (9%) in indemnity plans and an "other/ unknown" category.
• Of patients initiating treatment with venlafaxine, 48% were seen by GP/FPs and 13% by psychiatrists. Of patients initiating treatment with SSRIs, 45% were seen by GP/FPs and 10% by psychiatrists. The percentages of patients seen by internal medicine specialists (17%) and psychologists (3%) were the same in the 2 drug-class cohorts.
Switchers Versus Non-Switchers
In both cohorts, switchers were slightly younger than nonswitchers (P < 0.01, Table 1 ). Although there was no significant difference in gender distribution between the switch and nonswitch SSRI patients, the proportion of females was higher among the patients who switched from venlafaxine to SSRI than among the patients who continued on venlafaxine (74.1% vs. 69.2%, P = 0.007). In both drug classes, switchers had higher post-index rates of all-cause service utilization in hospital settings (more than 50% higher, P < 0.001) and ER utilization (more than 20% higher, P < 0.01) than did non-switchers (Table 1) . Logistic regression models evaluated factors associated with the likelihood of switching (Table 2) . Patients aged 18 to 39 years were more likely to make a drug-class switch than those in any other age group. Patients were less likely to switch if they had a diagnosis of hypertension (odds ratio Furthermore, switching was associated with high all-cause cost in the pre-index period, indicating that patients with higher baseline health care costs prior to antidepressant initiation were more likely to make a switch.
Patients who switched had higher costs than did nonswitchers, regardless of the index antidepressant drug class Higher depression-related costs for SSRI switchers than for non-switchers were partly due to higher antidepressant costs examined cost differences between switchers and non-switchers, controlling for other variables potentially influencing costs, including demographics, payer type, prior comorbidities, and physician specialty, and adjusting for the skewness in the cost data by log-transforming the dependent variables. These results confirm that switchers had significantly higher all-cause and depression-related treatment costs than non-switchers. Controlling for confounding variables, the extent of higher cost among switchers relative to non-switchers (in percentage terms) was more pronounced than the unadjusted percentages shown in Table 3 . After adjustment, all-cause health care costs were higher for switchers than non-switchers, both for SSRI-treated and venlafaxine-treated patients (67.5% and 37.3% higher, respectively, both comparisons P < 0.001). Adjusted depression-related costs were also higher for switchers than for non-switchers (147.0% for SSRI-treated and 35.4% for venlafaxine-treated patients, both comparisons P < 0.001).
Pre-Switch Versus Post-Switch Costs Among Switchers
Of 1,645 patients switching from an SSRI to venlafaxine, 122 (7.4%) switched less than 1 month after the index date (i.e., < 30 days pre-switch drug therapy and observation), and an additional 150 (9.1%) switched less than 1 month before the study end date (i.e., < 30 days post-switch drug therapy and observation). Of 733 patients who switched to an SSRI after beginning therapy with venlafaxine, the numbers of patients switching less than 1 month after the index date and before the study end date, respectively, were 58 (7.9%) and 45 (6.1%). For these patients and time periods, monthly costs were calculated using an assumed 1 month of observation. Using these assumptions, while switchers were more costly than non-switchers throughout the 12-month follow-up after therapy initiation, once they switched to the new drug class, their health care costs declined (Table 5 ). For SSRI-to-venlafaxine switchers, mean monthly all-cause total (medical plus pharmacy) costs declined from the pre-switch to the post-switch period by 19.5% ($682 [$1,708] vs. $549 [$1,308], P = 0.002). Higher pharmacy costs were offset by lower medical costs. For venlafaxineto-SSRI switchers, all-cause costs did not decline enough to reach statistical significance; however, the highly skewed distribution in all-cause costs for venlafaxine-treated patients (SD of more than 4 times the mean in the post-index period) made interpretation of this finding difficult. Log of all-cause total costs-pre-period C-statistic = 0.578.
n/a 1.062 1.039 In most comparisons for the group of patients whose index drug was an SSRI, changes in median costs from the pre-switch to post-switch periods were not consistent with the findings based on means. This pattern could be attributable to either the method of analysis (i.e., calculating per-patient means and medians of per-month values without weighting for length of observation) or to high medical cost outliers; 1 patient in the SSRI group incurred depression-related medical costs of more than $20,000 monthly during the pre-switch period. Table 5 also reports the percentage of patients who had services provided in hospital settings and ER visits during the pre-switch and post-switch periods for both drug-class cohorts.
a The table displays results for only the significant variables (at the 95% level). Other (non-significant) variables in the model included payer class (Medicare, self-insured), comorbidities (joint disorders, soft tissue disorders, sinusitis, respiratory infection, refractory disorders, allergic rhinitis, acute pharyngitis), depression sub-types (single episode, recurrent, neurotic, not elsewhere classified), anxiety, post-traumatic stress disorder (acute reaction to stress), substance abuse, physician specialty (internal medicine, psychology, other: with general/family practice as the omitted category), and fluoxetine. GP/FP = general practitioner/family practitioner.
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For patients who switched from SSRI to venlafaxine, there was a significant reduction in the percentage of patients with use of hospital settings (from 10.6% of patients in the pre-switch period to 7.6% in the post-switch period, P = 0.003). No other significant changes in hospital setting or ER visit use were observed.
Single Versus Multiple SSRI Users Among SSRI Switchers
Costs were not only different between switchers and nonswitchers but also between SSRI-treated patients who switched within-class before making a switch to venlafaxine versus those who switched from a single SSRI to venlafaxine (Table 6) . Results indicate that all-cause total costs were significantly higher for SSRI patients with pharmacy claims for multiple SSRI drugs before venlafaxine therapy (P = 0.002). Although not reported here, descriptive data suggested that higher costs were attributable primarily to medical costs (e.g., ER, outpatient, and ancillary services). However, no significant association between use of multiple SSRIs and depression-related costs was observed. Table 7 shows costs before and after switch, comparing patients who go through 2 or more SSRIs before switching to venlafaxine (multiple SSRI switchers) with patients who switched from a single SSRI to venlafaxine (single SSRI switchers), again assuming an observation period of 1 month for pre-switch or post-switch time periods less than 1 month. For the single SSRI switchers, mean monthly all-cause medical cost declined by 30.5% (P = 0.001) after the switch, and pharmacy cost increased by 34.2% (P < 0.001). The total (medical plus pharmacy) cost declined by 19.6% (P = 0.016) despite higher pharmacy cost. For the multiple SSRI switchers, all-cause medical and total cost changes were not significant, but all-cause pharmacy cost increased by 37.0% (P = 0.005). For both cohorts, depressionrelated medical cost decreased, but significantly so only for the single SSRI switchers (P = 0.005). Pharmacy costs increased significantly for both cohorts (P < 0.001). Total (medical plus pharmacy) depression-related cost did not show any significant change in either cohort.
■■ Discussion
The purpose of this analysis was to examine the rate and cost outcomes of switches between antidepressant classes (SSRIs and SNRIs). Of particular interest was assessing the total (medical plus pharmacy) costs of patients who switch versus those who do not and the change in total costs from pre-switch to postswitch. Results of this analysis suggest that patients who switch medications incur higher costs than those who remain on their initial medication; however, total costs decrease after switching to a different medication class.
Although switching of antidepressants has been a subject of recent studies and discussions, very few previous studies have provided numeric estimates of the extent of drug-class switching (outside of clinical-trial settings). Prior naturalistic studies have primarily measured switch rates within the SSRI class (1) and (3) [20] ). e 
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also controlled for individual drug (fluoxetine, citalopram, sertraline, paroxetine). b General linear model coefficient for variable (coded yes=1, no=0) representing switch from SSRI to venlafaxine (equations 1 and 3, N=43,653) or venlafaxine to SSRI (equations 2 and 4, N = 5,297). c θ = exp(β)-1 (Percentage increase in cost for switchers relative to non-switchers). d S θ = exp(β)S β (Standard error of the percentage difference
Dependent variables are log-transformed costs for the 12 months following initiation of treatment with either SSRI (equations 1 and 3) or venlafaxine (equations 2 and 4). SSRI=selective serotonin reuptake inhibitor.
or between SSRI and TCA classes. For example, using claims data for 1995-1996, Russell et al. compared switch rates across different SSRIs (within the SSRI class) during a 1-year window, finding rates ranging from 12% to 21%. 21 Using another database, Way et al. found that between 10% to 18% of patients taking fluoxetine, paroxetine, and sertraline switched to a second antidepressant and, of those, between 49% to 52% switched to a drug of the same class. 22 However, because the focus in the present study was on switching between 2 different drug classes, we would expect switch rates to be lower; in fact, switch rates between venlafaxine and each of the 4 SSRIs in the present study ranged between 2% to 6% (i.e., of 5,297 patients initiating treatment with venlafaxine, 2% switched to fluoxetine, 3% to sertraline, 3% to paroxetine, and 6% to citalopram). Another finding of interest is the SSRI cycling before switching drug class. Among switchers, multiple SSRI users generally incur higher all-cause costs (but not higher depression-related costs) than single SSRI users. While both groups experienced lower costs after switch, the change was statistically significant only for switchers from a single SSRI. Clinically, the prospects of response or remission decline with successive trials of antidepressants. 3, 17 However, this result cannot be interpreted in this study because of insufficient statistical power for this analysis (i.e., the number of patients switching antidepressant class after multiple SSRIs was 163, compared with 1,482 for patients switching to venlafaxine after just 1 SSRI).
Patients who switched medication, on average, incurred 20% to 40% higher total costs than those who did not switch. It is well recognized that treatment-resistant patients tend to have increased morbidity and mortality associated with their depression and other comorbid medical conditions. 10, 23 To address this issue, we attempted to control for comorbidities in our multivariate analyses. In the present study, after controlling for selected comorbidities, we still found switchers to have higher all-cause and depression-related costs than non-switchers, irrespective of index treatment (SSRI or venlafaxine); however, it is possible that unobserved disease severity or other unmeasured factors may also be contributing to the higher costs, as indicated by the R 2 values for the cost analyses, which ranged from 0.041 to 0.162.
In a study of SSRI use patterns and cost, Eaddy et al. (2005) found that mean all-cause, provider-submitted medical charges (excluding pharmacy costs) were approximately 50% higher ($7,858) for patients who experienced either a switch or augmentation in therapy and about 40% higher ($6,289) for patients with < 90 days of SSRI treatment compared with those who remained on their initial medication for ≥ 90 days and did not switch ($5,143, P < 0.001).
24 There was no difference in mean total all-cause costs for the > 90-day cohort and the < 90-day cohort when the pharmacy charges, including antidepressants, were included ($7,454 and $7,829, respectively, P = 0.606). 24 However, Curtiss observed, in an accompanying editorial, that the < 90-day group actually received an average of approximately 150 total days of SSRI drug therapy during the 365-day follow-up period due to the short period (15 days) for defining a gap in therapy, causing this short-term therapy group to be composed of early discontinuation as well as episodic use.
25 The < 90 days group in the study by Eaddy et al. also had an apparent higher severity of illness as measured by 3 proxy measures: Charlson Comorbidity Index, comorbid anxiety disorder, and use of "mental health specialty care" (i.e., psychiatrist or other mental health professional). Curtiss also pointed out that the proportion of patients that continue therapy with a given SSRI for at least 90 days is small: 16% in the study by Eaddy The present study also examined pre-switch and post-switch costs and utilization in an effort to understand the economic aspects of antidepressant switching. The source of these higher costs needs to be examined more closely in future studies. Once switched, switchers experienced lower mean treatment costs compared with their pre-switch status. To the extent that man- agement of therapy contributes to better patient outcomes, one would expect even higher-cost patients to experience cost reductions after switching therapy, although this reduction could, in part, be simply due to regression to the mean. Following a switch to a different antidepressant class, mean depression-related medical (excluding pharmacy) costs decreased by approximately 66% in patients switching from SSRI to venlafaxine and 61% in patients switching from venlafaxine to any SSRI. The reductions in medical costs more than offset a 62% increase in antidepressant costs for those switching from SSRI to venlafaxine and augmented the 17% pharmacy cost savings for those switching from venlafaxine to SSRI. Thus, medical costs played an important role in explaining cost differences not only between switchers and non-switchers but also between preswitch and post-switch costs for the switchers. This study further underscores the need for studying pharmacy and medical costs as well as mental and non-mental health care costs in combination because higher cost in 1 category may be offset by lower cost in another category.
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Limitations
The foremost limitation of this study is that the data are 6 years old. Among the changes that have taken place in 6 years is the addition of duloxetine to the SNRI class, the availability in generic 
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form of bupropion immediate release and bupropion sustained release, and the availability of almost all of the SSRIs in generic form. The widespread availability of most SSRIs and bupropion in generic form results in low (generic drug) copayments for health plan members and creates greater opportunity for health plans to implement step-therapy requirements such as that defined previously by Dunn et al. 26 For patients who do not receive benefit from the initial medication (be it branded or generic), a switch to an alternative antidepressant in the same or different class may provide improved therapeutic effect.
Second, our definition of a switch did not account for gaps in treatment between the end of the index drug therapy and the start of the new medication. While the mean number of days gap in therapy was 60 for those switching from an SSRI to venlafaxine and 61 for those switching from venlafaxine to an SSRI, patients could have had several months gap in antidepressant drug therapy before the switch occurred. Thus, some of the switches that we identified might actually have been new episodes.
Third, the follow-up period after the switch could have been short (e.g., 10 patients [9 with an SSRI and 1 with venlafaxine as the index medication] had 360 pre-switch days and 0 days post-switch).
Fourth, our group of switchers included a small number (n = 7) of patients whose index date and the start date of the new medication were the same day (i.e., the patient "switched" on the index date of therapy).
Fifth, retrospective database studies are subject to several limitations, including the inability to attribute causality to outcomes because of potential confounding, as well as possible allocation (selection) bias. In comparing the costs of switchers and non-switchers, even with statistical techniques aimed at accounting for baseline differences, it is likely that not all bias can be accounted for; patients might be switching for reasons not always collected or documented in administrative databases. The c-statistic for our logistic regression analysis of factors associated with an antidepressant class switch indicated that the model had a relatively low, 58%, predictive accuracy, suggesting that unmeasured confounding factors accounted for much of the decision to switch. The bias associated with these potential confounding factors should be less of an issue in comparing pre-switch with postswitch costs in those who did indeed switch medication (because the same patient group is used in each period by design), but there is no way to confirm this supposition.
Sixth, claims analysis can also suffer from miscoding of information and consequent biases in estimation. In this analysis, approximately 80% of patients were identified based on the ICD-9-CM code 311 (depression not elsewhere classified), a non-specific diagnosis code. However, in practice, ICD-9-CM code 311 is often the only code available on a clinic's administrative encounter form. Thus, the preponderance of 1 specific ICD-9-CM code is more likely due to administrative practice than inability to accurately diagnosis depression. 27 Seventh, our analysis of pre-switch and post-switch costs calculated per-patient mean and median values of per-month averages, without weighting the observations for length of observation. Eighth, when the actual pre-switch or post-switch observation time period was less than 1 month in duration, our denominator for the calculation was set to 1 month. This limitation, which affected 272 (16.5%) patients switching from an SSRI to venlafaxine and 103 (14.1%) patients switching from venlafaxine to an SSRI, had the effect of reducing the calculated "monthly" cost values (because we assumed 30 days when the actual number of days could have been much less). Thus, our results are not necessarily equal to those that would have been obtained in more standard per-patient-per-month calculations (i.e., the sum of costs divided by the sum of patient months across the entire patient group). Finally, for the patients initially treated with an SSRI, analysis of median values generally did not support the results obtained in the analysis of means, suggesting that results of the analysis could have been attributable to high-cost outliers.
■■ Conclusions
In the current study, we focused on the resource utilization and economic outcomes associated with drug-class switching and found some evidence to suggest that, although antidepressant drug-class switchers incur higher health care costs than do patients who continue treatment with the initially dispensed antidepressant, their medical costs (i.e., costs associated with physician visits, hospitalizations, etc.) are lower after the switch. This decline in medical costs helps offset the increase in pharmacy cost due to higher drug acquisition costs. This finding is consistent with results presented in the clinical literature showing improved response and remission rates for patients after they switch to an alternative antidepressant class.
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